Abstract: The present invention provides a pharmaceutical composition for inhibiting pathologic angiogenesis and/or cell proliferative disorder. The pharmaceutical composition of the present invention comprises an effective amount of LECT2 protein or analogue thereof, and a pharmaceutically acceptable carrier.
Abstract: This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of As2O3, As2S3, As2S2, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i). This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the radioactive arsenic-containing compound and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the treatment of tumors/cancers such as hematological malignancies and solid tumors.
Type:
Grant
Filed:
July 30, 2007
Date of Patent:
September 28, 2010
Assignees:
Institute of Nuclear Energy Research Rocaec, TTY Biopharm Company, Limited
Abstract: This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of As2O3, As2S3, As2S2, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i). This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the radioactive arsenic-containing compound and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the treatment of tumors/cancers such as hematological malignancies and solid tumors.
Type:
Application
Filed:
July 30, 2007
Publication date:
January 3, 2008
Applicants:
TTY Biopharm Company, Limited, Institute of Nuclear Energy Research Rocaec
Abstract: Pharmaceutical compositions containing taxanes having about 5 to about 75% phospholipid, about 0.01 to about 50% of a surfactant of an HLB value greater than 10, about 0.01 to about 50% alcohol and about 0.01 to about 40% taxane(s) or a derivative thereof.
Type:
Application
Filed:
August 2, 2005
Publication date:
February 8, 2007
Applicant:
TTY BIOPHARM COMPANY LIMITED
Inventors:
Yu-Fang Hu, Yao-Kun Huang, Shian-Bin Ye
Abstract: The invention relates to a pharmaceutical composition for the treatment of skin neoplasm, which comprises a therapeutically effective amount of arsenic trioxide and a pharmaceutically acceptable carrier. Furthermore, the invention also relates to a method of treating skin neoplasm in a human by administering to a human in need thereof a therapeutically effective amount of a pharmaceutical composition comprising arsenic trioxide.
Abstract: This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of As2O3, As2S3, AS2S2, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i).
Type:
Application
Filed:
March 3, 2004
Publication date:
October 28, 2004
Applicants:
TTY BIOPHARM COMPANY, LIMITED, INSTITUTE OF NUCLEAR ENERGY RESEARCH ROCAEC
Abstract: The invention mainly discloses a pharmaceutical composition for use in the treatment of hepatocellular carcinoma, which comprises thalidomide and a pharmaceutically acceptable carrier.